摘要
嵌合抗原受体(CAR)T(CAR-T)细胞疗法作为一种新兴的治疗策略,在难治性神经系统自身免疫性疾病(NADs)中展现出显著的治疗潜力。针对这一创新发展,中国专家结合临床试验结果,并充分考虑中国医疗实际需求,制订了《嵌合抗原受体T细胞治疗难治性神经系统自身免疫性疾病专家共识(2025年版)》。该共识涵盖了患者筛选、产品选择、治疗程序、监测流程、不良反应处理等方面,为临床实践提供了规范化指导。该共识主要针对NADs进行了详细阐述,更加注重中国患者的实际情况,并提出了便于临床实践的实施方案,为中国神经科领域推广CAR-T细胞治疗提供了重要的指导。
Chimeric antigen receptor(CAR)T(CAR-T)cell therapy has emerged as a promising treatment strategy for relapsed neurological autoimmune diseases(NADs).In response to this innovative approach,Chinese experts,combining clinical trial results and fully considering the actual medical needs in China,have developed the"Expert consensus on chimeric antigen receptor T cell therapy for neurological autoimmune diseases in China 2025".This consensus provides comprehensive guidelines on patients and cell product selection,treatment procedures,monitoring protocols,adverse event management,with the goal of standardizing clinical practice for CAR-T cell therapy in NADs.The consensus focuses on NADs,pays more attention to the actual situation of Chinese patients,and proposes implementation plans that are convenient for clinical practice,providing important guidance for the promotion of CAR-T cell therapy in the field of neurology in China.
作者
秦川
田代实
刘雨欣
王伟
Qin Chuan;Tian Daishi;Liu Yuxin;Wang Wei(Department of Neurology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)
出处
《中华神经科杂志》
北大核心
2025年第4期341-346,共6页
Chinese Journal of Neurology
关键词
神经系统自身免疫性疾病
嵌合抗原受体T细胞
细胞治疗
Neurological autoimmune diseases
Chimeric antigen receptor T cell therapy
Cellular therapy
作者简介
通信作者:王伟,Email:wwang@tjh.tjmu.edu.cn。
